Risk factors and drugs in the treatment of hypertension.
A wide range of drug classes, frequently including centrally acting agents, has been used in clinical trials in hypertension which have shown benefit. Although therapy has clearly limited the complications of hypertension, further improvement is needed, especially concerning coronary artery disease. Future interest therefore centres on drugs that do not worsen diabetes mellitus, do not cause dyslipidaemia, or induce potassium loss, while not provoking drowsiness, depression, other troublesome side-effects, or being associated with rebound hypertension when stopped. The centrally acting imidazoline agonists merit detailed study in this regard.